Literature DB >> 19321511

Clinical expression of leflunomide-induced pneumonitis.

Batsi Chikura1, Steven Lane, Julie K Dawson.   

Abstract

OBJECTIVES: To review all the current evidence of LEF-induced pneumonitis (LEIP) which will help rheumatologists recognize suspected cases of LEIP and to influence clinical guidelines.
METHODS: Thirty-two reported cases of LEIP (13 males and 19 females) were identified from a literature search and classified using Searles and McKendry's classification criteria. Their clinical characteristics were reviewed.
RESULTS: All patients had a history of either exposure to MTX or interstitial lung disease (ILD) or both and all patients had RA. Most patients (82%) had LEIP within the first 20 weeks of initiation of LEF. All patients who had a loading dose LEF and most patients with ILD developed LEIP early (within 12 weeks of exposure). Case mortality was 19%. Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP. There was a high mortality in the following groups of patients: diffuse alveolar damage (DAD) on histological examination, pre-existing ILD and ground glass shadowing on high resolution computerised tomography (HRCT). Treatment with cholestyramine did not appear to alter clinical outcome.
CONCLUSIONS: LEIP usually occurs within the first 20 weeks of initiation of LEF. Clinical features of patients who died were pre-existing ILD, ground glass shadowing on HRCT and DAD on histological examination, and these could be poor prognostic indicators. Patients need to be made aware of this rare complication. LEF should not be used in patients with previous MTX-P and should be used with caution in patients with ILD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321511     DOI: 10.1093/rheumatology/kep050

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis.

Authors:  Pieter C Goeminne; Patrick Verschueren; Hans Scheers; Lieven J Dupont
Journal:  Clin Rheumatol       Date:  2011-09-22       Impact factor: 2.980

2.  Pulmonary function test: its correlation with pulmonary high-resolution computed tomography in patients with rheumatoid arthritis.

Authors:  Daza Leonel; Cervantes Lucia; Muñiz A; Hernández Martha-Alicia; Murillo Blanca
Journal:  Rheumatol Int       Date:  2011-04-17       Impact factor: 2.631

Review 3.  [Rheumatic patients in the intensive care unit].

Authors:  P Lehmann; T Brünnler; B Salzberger; M Fleck
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-02       Impact factor: 0.840

4.  [Pulmonary emergencies in connective tissues disorders and vasculitides].

Authors:  J O Schröder; R A Zeuner; B Bewig; M Both
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 5.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 6.  Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.

Authors:  Rekha Vij; Mary E Strek
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

7.  Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma.

Authors:  Mark J Hamblin; Maureen R Horton
Journal:  Pulm Med       Date:  2011-06-04

Review 8.  The multifaceted aspects of interstitial lung disease in rheumatoid arthritis.

Authors:  Lorenzo Cavagna; Sara Monti; Vittorio Grosso; Nicola Boffini; Eva Scorletti; Gloria Crepaldi; Roberto Caporali
Journal:  Biomed Res Int       Date:  2013-09-25       Impact factor: 3.411

9.  Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.

Authors:  Bryant R England; Harlan Sayles; Kaleb Michaud; Geoffrey M Thiele; Jill A Poole; Liron Caplan; Brian C Sauer; Grant W Cannon; Andreas Reimold; Gail S Kerr; Joshua F Baker; Ted R Mikuls
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.